DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for encephalitis — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEncephalitis maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for encephalitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glutamate metabotropic receptor 5 (GRM5) — GRM5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TAO · 2.9 Å · ligand (S)-2-AMINO-3-(3,5-DIOXO-[1,2,4]OXADIAZOLIDIN-2-YL)-PROPIONIC ACID (QUS). Experimental structure, not a prediction.
What the evidence adds up to
Annual incidence of encephalitis in non-outbreak settings ranges from 0.07 to 12.6 cases per 100,000 population, with an evident decrease over time. Across 41 studies, more than half of cases had unknown cause in 26 of them. Meta-regression found that study period, setting, and subsyndrome contributed to between-study variation, not methodological factors like study design or testing strategies. The authors hypothesise that new or emerging infectious agents, or new forms of immune-mediated encephalitis, may account for cases currently of unknown cause.
Metagenomics and proteomics are being applied to diagnosis in idiopathic encephalitis. Unbiased sequencing of biological samples, followed by rapid computational algorithms to determine pathogen-derived nucleic acids, recently identified a case of neuroleptospirosis, leading to the patient's dramatic clinical improvement with intravenous penicillin. Metagenomics also enabled discovery of a neuroinvasive astrovirus in several patients. For autoimmune encephalitis, phage display of human peptides discovered autoantibodies against tripartite motif family members in a patient with paraneoplastic encephalitis, and a complementary assay using ribosomes to display full-length human proteins identified additional autoantibody targets. In a case of severe progressive encephalitis, next-generation sequencing provided a quick and definite diagnosis of the specific pathogen, enabling appropriate treatment.
In a case series of 13 children with encephalitis admitted to inpatient rehabilitation between 1996 and 2010, mean age was 9 years, 54% male. Mean Functional Independence Measure for Children Total Developmental Functional Quotient at admission was 37 and at discharge was 64, an average change of 26.7. Self-care, cognition, and mobility domain scores all improved significantly. However, 11 of the 13 children still displayed significant functional impairments, defined as a DFQ of 85 or less, at discharge. Key clinical features were diverse and not related to functional outcome.
Three human viruses illustrate how new viral encephalitides emerge: Nipah virus after molecular evolution of a new zoonotic viral genus within the Paramyxovirinae family; Human Herpesvirus-6 in immune suppressed human hosts harbouring this typically benign herpesvirus; and West Nile virus after translocation of this mosquito-borne virus to a distant geographic region with immunologically naive avian and human hosts. What remains missing is systematic work to identify predictors of functional outcome in children, and a better understanding of the causes of the large proportion of cases with unknown aetiology, which would require sustained funding for metagenomic and proteomic diagnostic research, prospective trial designs that stratify patients by subsyndrome and immune status, and global coordination to capture emerging pathogens before they become widespread.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2010 · 194 citations
Challenge of the unknown
AbstractBACKGROUND: The threat of emerging infections and recognition of novel immune-mediated forms of encephalitis has raised the profile of this condition in recent years. Incidence is poorly defined and most cases have an unknown cause. There is currently much interest in identification of new microbial agents of encephalitis, but no work has investigated systematically reasons for lack of pathogen identification in studies. METHODS: We systematically reviewed published literature on incidence and etiology of encephalitis in non-outbreak settings and explored possible explanations for the large number of cases of unknown etiology. RESULTS: Annual incidence ranged from 0.07 to 12.6 cases per 100,000 population with an evident decrease over time (p = 0.01). The proportion of cases with unknown etiology was high across studies (>50% in 26 of 41 studies), with strong evidence of heterogeneity in study findings (p < 0.001). Our meta-regression identified study period, setting, and subsyndrome to be the main contributors to between-study variation, rather than methodologic factors such as study design, case definitions, sample types, and testing strategies. CONCLUSIONS: Our findings support the hypothesis that new and emerging infectious agents, or new forms of immune-mediated encephalitis, may be responsible for cases currently of unknown cause and encourage the ongoing global effort to identify these. Our review highlights research areas that might lead to a better understanding of the causes of encephalitis and ultimately reduce the morbidity and mortality associated with this devastating condition.
Current Opinion in Neurology · 2015 · 33 citations
A tale of two approaches
AbstractPURPOSE OF REVIEW: We highlight how metagenomics and proteomics-based approaches are being applied to the problem of diagnosis in idiopathic encephalitis. RECENT FINDINGS: Low cost, high-throughput next-generation sequencing platforms have enabled unbiased sequencing of biological samples. Rapid sequence-based computational algorithms then determine the source of all the nonhost (e.g., pathogen-derived) nucleic acids in a sample. This approach recently identified a case of neuroleptospirosis, resulting in a patient's dramatic clinical improvement with intravenous penicillin. Metagenomics also enabled the discovery of a neuroinvasive astrovirus in several patients. With regard to autoimmune encephalitis, advances in high throughput and efficient phage display of human peptides resulted in the discovery of autoantibodies against tripartite motif family members in a patient with paraneoplastic encephalitis. A complementary assay using ribosomes to display full-length human proteins identified additional autoantibody targets. SUMMARY: Metagenomics and proteomics represent promising avenues of research to improve upon the diagnostic yield of current assays for infectious and autoimmune encephalitis, respectively.
Journal of Pediatric Rehabilitation Medicine · 2013 · 16 citations · open access
Functional status of children with encephalitis in an inpatient rehabilitation setting: A case series
AbstractINTRODUCTION: Patterns and predictors of recovery from encephalitis are poorly understood. METHODS: This study examined functional status and reviewed charts of all children who presented to a pediatric inpatient rehabilitation facility with encephalitis between 1996 and 2010. Functional status at admission and discharge from inpatient rehabilitation was evaluated using the Functional Independence Measure for Children (WeeFIM) Self-care, Mobility, Cognitive, and Total Developmental Functional Quotient scores (DFQ, % of age-appropriate function). Charts were reviewed to characterize key clinical features and findings. RESULTS: Of the 13 children identified, the mean age was 9 years (range 5-16) with 54% males. Mean WeeFIM Total DFQ at admission was 37 (range: 15-90) and at discharge was 64 (range: 16-96). Average change in WeeFIM Total DFQ from admission to discharge was 26.7 (range 0-55, p < 0.001). WeeFIM domain scores improved between admission and discharge (Self-Care: p < 0.001, Cognition: p < 0.01, Mobility: p < 0.001). Eleven children displayed significant impairments in functional skills, defined as DFQ of < or =85, at discharge. Key clinical features and findings were diverse and not related to functional outcome. CONCLUSIONS: Results suggest that significant functional improvement in children with encephalitis occurs during inpatient rehabilitation. Further research is necessary to identify predictors of outcome in children with encephalitis.
AbstractBACKGROUND: Viral encephalitis occurs in epidemic settings or is sporadic. New encephalitis patterns reflect the roles that biologic reservoirs and vectors play in determining virus-human interactions. "New" viral encephalitis can also result from human host modifications that increase susceptibility to neuroinvasive viral infection. REVIEW SUMMARY: Three human viruses, Nipah virus, Human Herpesvirus-6, and West Nile virus, present examples of how "new" viral encephalitides emerge in a specific geographic region or clinical setting. Nipah virus encephalitis emerged after the molecular evolution of a new zoonotic viral genus within the Paramyxovirinae family. Human herpesvirus-6 encephalitis has emerged in the immune suppressed human host harboring this ubiquitous but typically benign herpesvirus. West Nile virus encephalitis has emerged in the Western hemisphere after apparent abrupt translocation of this mosquito-borne virus to a distant geographic region with immunologically naive avian and human hosts. CONCLUSION: While the clinical features of these viral encephalitides are somewhat distinct, they each emerged as the result of human-derived factors that altered the biologic dynamic between humans and their viral pathogens.
Virology Journal · 2019 · 12 citations · open access
Rapid detection of human herpes virus by next-generation sequencing in a patient with encephalitis
AbstractBACKGROUND: The inflammatory or non-inflammatory changes caused by the virus entering the nervous system and related tissues are central nervous system virus infections. Viral infection is a common infectious disease of the central nervous system, of which herpes simplex virus encephalitis is the most common. However, conventional laboratory techniques to detect an infectious agent are difficult to achieve etiological diagnosis. CASE PRESENTATION: Here we present a patient with severe and progressive encephalitis, requiring diagnosis of the specific pathogen to guide clinical treatments. CONCLUSIONS: Application of next-generation sequencing provided a quick and definite diagnosis of the etiology of encephalitis and enabled our patient to be treated appropriately.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
